All In Biotech

Drug Trial Radar · NCT06447662

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

64

Actual

Start

Jun 27, 2024

Primary completion

Oct 9, 2026

Study completion Oct 9, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body. Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control. Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels. All participants in this study will take the study medication (PF-07934040) as pill by mouth twice a day repeating for 21-day or 28-day cycles. Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07934040 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at various times (depending on the treatment) during the 21-day or 28-day cycle. Participants can continue to take the study medication (PF-07934040) and the combination anti-cancer therapy until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective. Participants will be involved in this study for up to 4 years. During this time, they will come into the clinic between 1 to 4 times in each 21-day or 28-day cycle. After they have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing.

Conditions

  • Carcinoma, Pancreatic Ductal
  • Colorectal Neoplasms
  • Carcinoma, Non-Small-Cell Lung

Interventions

  • PF-07934040Drug

    panKRAS inhibitor

  • GemcitabineCombination product

    Chemotherapy (antimetabolite)

  • Nab-paclitaxelCombination product

    Taxane-type Chemotherapy

  • CetuximabCombination product

    Monoclonal Antibody (EGFR Inhibitor)

  • FluorouracilCombination product

    Part of FOLFOX chemotherapy regimen cytotoxic chemotherapy (antimetabolite and pyrimidine analog)

  • OxaliplatinCombination product

    Part of FOLFOX Chemotherapy Regimen platinum based compound (alkylating agent)

  • LeucovorinCombination product

    Part of FOLFOX chemotherapy regimen Folic Acid Analog

  • BevacizumabCombination product

    VEG-F inhibitor

  • PembrolizumabCombination product

    immune checkpoint inhibitor (PD-1 inhibitor)

  • pemetrexedCombination product

    Can be used in Platinum-based Chemotherapy regimen Antimetabolite

  • CisplatinCombination product

    Can be used as part of Platinum-based chemotherapy regimen Platinum-based antineoplastic (alkylating agent)

  • PaclitaxelCombination product

    Can be used in Platinum-based chemotherapy regimen Taxane

  • CarboplatinCombination product

    Can be used as part of a platinum-based chemotherapy regimen platinum containing compound (alkylating agent)

  • SasanlimabCombination product

    immune checkpoint inhibitor (PD-1 inhibitor)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 & 2: Incidence of Adverse Events (AEs)Time frame: Start of treatment up to 30 days after last dose or start of new anticancer therapy (whichever occurs first)
  2. PART 1 & 2: Number of participants with laboratory abnormalitiesTime frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
  3. Part 1: Number of participants with Dose-limiting toxicities (DLT)Time frame: Baseline up to 28 days
  4. Part 2: Objective Response - Number of Participants With Objective Response (alone or in combination)Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years'

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group, PA

    Fayetteville, Arkansas

  • Highlands Oncology Group, PA

    Rogers, Arkansas

  • Highlands Oncology Group

    Springdale, Arkansas

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California

  • City of Hope Investigational Drug Service (IDS)

    Duarte, California

  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)

    Aurora, Colorado

  • University of Colorado Hospital - Anschutz Outpatient Pavilion

    Aurora, Colorado

  • University of Colorado Hospital- Anschutz Cancer Pavilion (ACP)

    Aurora, Colorado

  • University of Colorado Hospital

    Aurora, Colorado

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia

  • START Midwest

    Grand Rapids, Michigan

  • Siteman Cancer Center - St Peters

    City of Saint Peters, Missouri

  • Siteman Cancer Center - West County

    Creve Coeur, Missouri

  • Siteman Cancer Center - North County

    Florissant, Missouri

  • Siteman Cancer Center

    St Louis, Missouri

  • Barnes-Jewish Hospital

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Siteman Cancer Center - South County

    St Louis, Missouri

  • Duke University Medical Center, lnvestigational Chemotherapy Service

    Durham, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio

  • West Chester Hospital

    West Chester, Ohio

  • Rhode Island Hospital

    Providence, Rhode Island

  • Miriam Hospital

    Providence, Rhode Island

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Pan American Center for Oncology Trials, LLC

    Rio Piedras, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.